Adding GSI, a pharmacological blocker of Notch signaling, rescued the oHSV-induced immunosuppressive TME and activated CD8+ T cell-dependent anti-tumor memory responses, resulting in therapeutic benefits [98]. This evidence concerns the gene CD8A and neoplasm.